key: cord-1009644-x7l4u8ev
authors: Babic, N.; Garner, K.S.; Hirschhorn, J.W.; Zebian, R.; Nolte, F.S.
title: Evaluation of Abbott ID NOW COVID-19 POC test performance characteristics and integration in the Regional Health Network workflows to improve health care delivery
date: 2021-12-08
journal: Clin Biochem
DOI: 10.1016/j.clinbiochem.2021.12.003
sha: f87f7b96efb8e4624d10cab1ad36771c7aaea4cd
doc_id: 1009644
cord_uid: x7l4u8ev

With the recent global surge of SARS CoV-2 Delta variant, there continues to be high demand for COVID-19 diagnostic testing. Abbott ID NOW is a rapid, CLIA-waived, COVID-19 diagnostic test ideally suited for use in urgent care settings or where access to diagnostic testing is limited. In this study we describe the results of rigorous validation of ID NOW and post-implementation study of POC test utilization patterns within community hospitals and clinics. Performance of ID NOW was validated by comparison of the results from 207 consecutive, paired, specimens tested on the ID NOW and on the m2000/Alinity m platforms. Once validated, ID NOW devices were placed for clinical use at four regional hospitals and clinics. We found that the ID NOW and m2000/Alinity m positive and negative percent agreement were 94.5% (95% CI, 85.1% to 98.1%) and 99.3% (95% CI, 96.4% to 99.9%), respectively. As of August 2021, a total of 2,301 tests were performed by ID NOW at individual regional network sites. The population tested consisted of 55.5% White and 42.9% Black patients, with Black patients presenting predominantly in the hospitals, while White patients were more evenly distributed between hospital and clinic sites. Disease prevalence observed among patients tested by ID NOW (12.3%) was aligned with overall prevalence seen at regional sites (11.3%). In summary, the ID NOW test can provide rapid and accurate results in a variety of near-to-patient and POC settings. If used correctly, it could serve as a valuable diagnostic tool to enable equal access to care and improve healthcare delivery within large health network systems.

With the recent surge of SARS CoV-2 Delta variant incidence across the US during the spring and summer of 2021, there continues to be high demand for COVID-19 diagnostic testing.

To meet demands for population-wide COVID-19 testing, many clinical laboratories, including our own, have implemented several SARS-CoV-2 diagnostic tests ranging from highly sensitive RT-PCR to rapid but less sensitive antigen tests. Although readily available, molecular testing is mostly limited to high complexity, Clinical Laboratory Improvement Amendment (CLIA) licensed clinical laboratories. Many regional, community and rural hospital laboratories do not have capability to perform molecular COVID-19 diagnostic testing due to their size or lack of expertise. In these settings availability of rapid and reliable CLIA-waived diagnostic tests is very important to help facilitate adequate health care delivery. Several rapid molecular tests have received Federal Drug Administration (FDA) Emergency Use Authorization (EUA) for CLIAwaived settings, such as testing at the point of care (POC) by minimally trained staff [1] . With capability to produce results in minutes, these platforms are best fit for clinical environments where timely result is necessary, such as patients presenting to EDs, urgent care facilities, or community hospitals and clinics that lack rapid access to diagnostic testing.

MUSC Health is an integrated health delivery system where our institution (MUSC Charleston) serves as the hub connected to four regional medical centers across the state of South Carolina (SC), comprising Regional Health Network (RHN). The RHN hospitals serve the following counties: Marion, Florence, Lancaster and Chester. According to the SC Department of Health data, the communities served by RHN medical centers have consistently had higher COVID-19 incidence compared to Charleston County, served by our institution [2] . Thus, in addition to expedited centralized testing performed at MUSC Charleston, an access to rapid testing that could be performed at POC (ie at each individual RHN site) in symptomatic patients was necessary to help proactively contain further outbreaks. Abbott ID NOW seemed to be an obvious POC testing choice due to its CLIA waived status and short turn-around-time of 13 minutes or less. However, there have been controversial reports regarding the clinical performance of this test, with reports of clinical sensitivity ranging from 55% to 91% [3] [4] [5] [6] [7] [8] [9] [10] [11] .

These reports necessitated a comprehensive evaluation of ID NOW performance in our patient population prior to implementation.

In this study we describe the results of rigorous validation of ID NOW in COVID-19 symptomatic patients presenting to the ED of the small South Carolina regional hospital and effectiveness of the combined diagnostic strategy approach in improving healthcare delivery within communities. and symptoms used to qualify patients followed the CDC guidelines in place at the time and included fever, cough, shortness of breath, nausea, vomiting, diarrhea, fatigue, headache and loss of taste and/or smell. All testing was performed by qualified laboratory personnel.

Dry NS samples provided with the kit were tested using the Abbott ID NOW ( and an internal control (hydroxypyruvate reductase gene from the pumpkin plant), takes place simultaneously in the same reaction. The test has a reported limit of detection of 100 copies/ml [12, 14] . Although the Abbott RealTime SARS-CoV-2 test is a qualitative test we have established the relationship between the cycle number (C n ) values and genomic copies/ml using dilutions of commercially available reference material quantified by digital droplet PCR (AccuPlex SARS-CoV-2 verification panel, SeraCare) [15] .

In this study each individual health network site was defined as a POC site. ID NOW devices were placed at all four RHN hospitals and associated family medicine, primary care and/or urgent care clinics, where significant influx of symptomatic patient has already been seen or was expected. All other patients were continued to be tested by centralized molecular testing at MUSC Charleston site. The patients tested at hospital sites were symptomatic patients who presented predominantly to the ED. The clinic patients presented mostly with mild/moderate symptoms consistent with COVID-19 infection. Clinical data for ID NOW was summarized for the time period ranging from 09/01/2020 to 08/23/2021.

Positive percent agreement (PPA) and negative percent agreement (NPA) along with corresponding Wilson 95% confidence intervals (CI) were calculated using a clinical method validation software package (Analyze-it). The paired analysis of positive PCR results was performed using univariate distribution plots (Analyze-it software). Population demographics and PCR testing statistics were provided by MUSC Health Analytics using Tableau software (Mountain View, CA) and EPIC SlicerDicer (Verona, WI).

Total number of patients tested at MUSC Marion during the validation process (June and between ID NOW and m2000 methods (n=34) is summarized in Fig. 1 testing volumes were approximately the same, the racial distribution differed between hospitals and clinics. Black patients were seen predominantly in the hospitals, whereas White patients were more evenly distributed between hospitals and clinics ( Figure 2) . Also, as shown in Figure   2 , utilization of ID NOW in clinics where patients presented with generally milder symptoms resulted in the same positivity rates as seen in more severely ill patients presenting to the hospitals.

In this study we evaluated performance characteristics of ID NOW and conducted postimplementation clinical utilization analysis of POC COVID-19 testing to determine the effectiveness of this approach within racially and socioeconomically diverse communities served by the MUSC Health network. Our goal was to ensure more equitable access to care for our entire patient population by providing a rapid diagnostic test for symptomatic patients residing, particularly those in remote and/or underserved area. Figure 1 , we observed more consistent distribution of concordant and discordant data across C n values. All discordant results observed were at C n values >24. Based on our results, the analytical sensitivity of ID NOW appears to be between 500 and 1,000 copies/mL, which is in line with ID NOW limit of detection of 511 copies/mL, reported by Fung et al [16] and significantly better than the other estimates published in literature [3, 8] .

In addition, a recent Cochrane systematic review of studies of rapid-point-of-care molecular tests for SARS-CoV-2 reported sensitivity and specificity for ID Now of 76.8% (95% CI 72.9% to 80.3%) and 99.6% (95% CI 98.4% to 99.9%), respectively for the six studies reviewed [17] . They also reported that ID NOW sensitivity rose to 100% when only samples with a C t values ≤30 were considered which is consistent with our findings. Moreover, clinical significance of detecting low levels of viral RNA is still not clear. Additional clinical studies are needed to determine if the false negative ID NOW results truly reflect the failure to detect actionable, active disease.

We had a single false-positive ID NOW result that may have resulted from specimen carry-over cross-contamination, poor collection of the NP swab or degradation of a low level of SARS-CoV-2 RNA during transport to the central laboratory. Taken together, our findings indicated that the performance characteristics of the ID NOW are comparable to the Abbott SARS-CoV-2 RNA assays run on the m2000 and Alinity m instruments in symptomatic patients.

Limitations to our validation study include that ID NOW was performed in the laboratory rather than as a true POC test by non-laboratory staff, the prevalence of infection among our study population was high, the ED population may represent the more severe end of the disease spectrum with higher viral burdens, and the confounding variable of the difference is in sample types used for ID NOW and the comparator tests. Comparing across anatomical sites, nasal cavity versus nasopharynx, may say more about the preferred anatomical niche of the virus rather than any meaningful difference in sensitivities between the assays used in this study.

Despite the validation study drawbacks outlined above, our post-implementation data of POC testing in various clinical settings suggest that this approach is suitable for community-wide suggesting that ID NOW can be effectively used in patients presenting with wide range and severity of symptoms. This is further supported by equal positivity rates observed between the hospitals and clinics (Figure 2 ).

By customizing our rapid testing approach to the needs of our community hospitals and clinics, we were able to provide immediate access to testing to symptomatic patients residing in high disease prevalence areas across the state. Our hope is that this strategy will not only help limit disease outbreaks within these communities but also lead to improved outcomes. A large cohort study conducted at the US Department of Veteran Affairs (VA), including close to 6 million patients revealed that while Black and Hispanic patients were more likely to test positive for COVID-19 than White patients, 30-day mortality did not differ by race [21] . Since VA patients generally have more equal access to care compared to general population, these results suggest that access to care rather than the race is stronger predictor of mortality in COVID-19

patients. This study also highlights a need for tailored testing strategy approach, such as described here, to contain and prevent disease outbreaks in racial and ethnic minority communities.

In summary, rapid testing has become an important tool in our COVID-19 diagnostic toolkit. It is now deployed within MUSC Health system as a true POC test for rapid identification and isolation of infected individuals, appropriate use of personal protective equipment, and initiation of special workflows required for emergency care and in time-sensitive outpatient settings. Future population-based outcome studies are needed to evaluate the effectiveness of this approach in enabling equal access to care and improving healthcare delivery to the communities across our health network. 

Food and Drug Administration

South Carolina County-Level Data for COVID-19

Comparison of Abbott ID NOW and Abbott m2000 methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from symptomatic patients

Evaluation of the COVID19 ID NOW EUA assay

Comparison of Abbott ID NOW, Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID

Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2

Performance of Abbott ID Now COVID-19 Rapid Nucleic Acid Amplification Test Using Nasopharyngeal Swabs Transported in Viral Transport Media and Dry Nasal Swabs in a New York City Academic Institution

Clinical Evaluation of Three Sample-to-Answer Platforms for Detection of SARS-CoV-2

Comparison of two commercial molecular tests and a laboratory developed modification of the CDC 2019-nCOV RT-PCR assay for the qualitative detection of SARS-CoV-2 from upper respiratory tract specimens. medRxiv

Diagnostic Performance of a Rapid Point-of-care Test for SARS-CoV-2 in an Urban Emergency Department Setting

Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche Cobas for the rapid detection of SARS-CoV-2

The COVID-19 XPRIZE and the need for scalable, fast, and widespread testing

ID Now COVID-19 Instructions for Use IN190000 Rev

Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance

Verification and validation of SARS-CoV-2 assay performance on the Abbott m2000 and Alinity m systems

Direct Comparison of SARS-CoV-2 Analytical Limits of Detection across Seven Molecular Assays

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

The Lines That Held Us: Assessing Racial and Socioeconomic Disparities in SARS-CoV

Social Determinants of Health Mediate COVID-19 Disparities in South Florida

Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study